Please use this link to access this publication: https://www.nature.com/articles/s41416-023-02466-w Abstract The side effects of cancer therapy continue to cause significant health and cost burden to the patient, their friends and family, and governments. A major barrier in the way in which these side effects are managed is the highly siloed mentality that results in a fragmented approach to symptom control. Increasingly, it is appreciated that many symptoms are manifestations of common underlying pathobiology, with changes in the gastrointestinal environment a key driver for many symptom sequelae. Breakdown of the mucosal barrier (mucositis) is a common and early side effect of many anti-cancer agents, known to...

Abstract There is a rapid spread of multiple sclerosis (MS) disorder across the globe. There are around 2.8 million cases of Multiple Sclerosis in the world; among them, 1 million are just present in the US. Many drugs have been tested on MS patients but there is no effective treatment for MS till now. Many agonists, such as dronabinol, and nabilone, have been used to treat MS. So, in this study, different compounds from Cannabis sativa to inhibit the symptoms caused by MS had been evaluated. This study targeted the Myelin oligodendrocyte glycoprotein receptor as it has shown some good results in experimental labs. In this study, binding...

Abstract Rheumatoid diseases, including rheumatoid arthritis, osteoarthritis, and fibromyalgia, are characterized by progressive inflammation in the musculoskeletal system, predominantly affecting the joints and leading to cartilage and bone damage. The resulting pain and ongoing degradation of the musculoskeletal system contribute to reduced physical activity, ultimately impacting quality of life and imposing a substantial socioeconomic burden. Unfortunately, current therapeutics have limited efficacy in slowing disease progression and managing pain. Thus, the development of novel and alternative therapies is imperative. Cannabinoids possess beneficial properties as potential treatments for rheumatoid diseases due to their anti-inflammatory and analgesic properties. Preclinical studies have demonstrated promising results in halting disease...

Please use this link to access this publication. Abstract Venous Thromboembolism (VTE) carries significant clinical implications, and with the rise in cannabis consumption, its potential influence on VTE outcomes warrants investigation. Using the National Inpatient Sample (NIS) database (2016–2019), we analyzed 2,217,184 hospitalized VTE patients. Among these, 1.8 % (38,810) reported cannabis use. We compared demographics, comorbidities, in-hospital outcomes, and quality metrics between cannabis users and non-users with VTE. Cannabis users were chiefly younger males (average age 45 in cannabis users vs. 62 in non-cannabis users) from lower-income brackets. Notably, 5.4 % discharged against medical advice. Although in-hospital mortality was initially lower for cannabis users (2.8 % vs. 5.1 %,...

Please use this link to access this publication: https://he02.tci-thaijo.org/index.php/anesthai/article/view/266158 Abstract Introduction: Nowadays, cannabis plays a larger role in medical treatment. However, there is a lack of evidence on the treatment of neuropathic pain patients in Thailand. This research aims to study the clinical efficacy of medical cannabis for relieving neuropathic pain and effects of neuropathic pain on quality of life. Methods: This is a cross-sectional study in non-palliative care patients with neuropathic pain treated with medical cannabis at Lampang Hospital from August 28, 2019 to October 3, 2021. The data about baseline characteristics, pain scores, quality of life and side effects were collected from outpatient...

Please use this link to access this publication: https://rapm.bmj.com/content/early/2023/11/03/rapm-2023-104833 Abstract Introduction Most Americans live in a state that has legalized cannabis as a medical treatment for pain, but it is unclear how chronic pain intensity relates to cannabis use. Our objective was to examine the association between patient-reported pain measures and cannabis among adults with chronic pain. Methods This cross-sectional study of a representative sample of adults reporting chronic non-cancer pain in 36 states and DC with active medical cannabis programs from March to April 2022 assessed cannabis use for chronic pain, categorized as active (within 30 days), past (>31 days), or never use (referent). Measures were pain...

Please use this link to access this publication: https://www.sciencedirect.com/science/article/abs/pii/S2352007823003244 Summary The therapeutic properties of cannabis have been recognized for thousands of years. The main active compounds in cannabis that have been scientifically proven to possess pharmacological properties are tetrahydrocannabinol (THC), cannabinol (CBN), and cannabidiol (CBD). Cannabinoids have been found to serve diverse functions in physiological processes and are recognized for their properties including but not limited to, appetite stimulation, pain relief, anticonvulsant effects, bronchodilation, sedation, hypnotic effects, and muscle relaxation. In general, cannabinoids exhibit a favorable safety profile as pharmaceutical agents. However, interaction with drug-metabolizing enzymes, including the cytochrome P450 (CYP) family and P-glycoprotein (P-gp), alters the metabolism of co-administered drugs that are also metabolized by these enzymes. This article...

Abstract It has been reported that cannabis consumption affects the anterior cingulate cortex (ACC), a structure with a central role in mediating the empathic response. In this study, we compared psychometric scores of empathy subscales, between a group of regular cannabis users (85, users) and a group of non-consumers (51, controls). We found that users have a greater Emotional Comprehension, a cognitive empathy trait involving the understanding of the “other” emotional state. Resting state functional MRI in a smaller sample (users = 46, controls = 34) allowed to identify greater functional connectivity (FC) of the ACC with the left somatomotor cortex (SMC), in users when compared to controls....

Abstract Background and objectives Medical cannabis use is increasing in Australia and other jurisdictions, yet little is known about the effects of medical cannabis on cognitive function. Findings from studies of non-medical (‘recreational’) cannabis may not be applicable to patients using prescribed medical cannabis to manage a health condition. Methods In this semi-naturalistic, open-label trial, patients with various health conditions attended a single laboratory session in which they self-administered a standard dose of prescribed medical cannabis as per instructions on the pharmacy label. We assessed cognitive performance using the Cambridge Neuropsychological Test Automated Battery (CANTAB) and Druid application (app) prior to and following (CANTAB:...

Abstract Cannabis is the most widely used recreational drug in the United States and regular use has been linked to deficits in attention and memory. However, the effects of regular use on motor control are less understood, with some studies showing deficits and others indicating normal performance. Eighteen users and 23 nonusers performed a motor sequencing task during high-density magnetoencephalography (MEG). The MEG data was transformed into the time-frequency domain and beta responses (16–24 Hz) during motor planning and execution phases were imaged separately using a beamformer approach. Whole-brain maps were examined for group (cannabis user/nonuser) and time window (planning/execution) effects. As expected, there were...